Trusted Press Release Distribution   Plans | Login    

Briefing Search


Author Details
Aryan Mishra

Bookmark and Share
Aortic Valve Market Performance and Market Share, Sales Revenue and Major Manufacturers Performance,
The global aortic valve market is forecasted to attain revenue of $13.6 billion by 2025, according to P&S Market Research., 7/12/2019 - The market is mainly driven by increasing prevalence of valvular diseases, increasing demand for minimally invasive surgeries (MISs), rise in number of clinical trials for heart valves, and introduction of advanced implants.

Access Detailed Report Summary:

On the basis of type of surgery, aortic valve market is segmented into MIS and open surgery. The adoption of these valves for MISs is expected to grow at a faster CAGR of 13.7% during the forecast period. MISs causes lesser trauma to the patient and facilitate quicker recovery than invasive procedures such as open-heart surgeries. Due to reduced prices and advantages, there is an increase in the adoption of minimally invasive procedures, which contribute in the growth of the market.

Request to Get the Sample Pages at:

During the forecast period, the aortic valve industry is expected to witness the fastest growth in demand in Asia-Pacific (APAC), at a CAGR of 13.0%, owing to the presence of large number of patient population with cardiovascular diseases, rising number of aortic valve replacement surgeries, growing medical tourism, and continuously improving healthcare infrastructure.

Make Enquiry Before Buying the Report: Click Here

Moreover, economic development and rising healthcare expenditure are some of the factors that are expected to boost the APAC aortic valve market over the forecast period. Growing number of approvals for transcatheter valves by companies such as Edwards Lifesciences Corporation, Medtronic plc, and others is also expected to contribute in the growth of the market. For instance, in March 2018, LivaNova plc announced the first patient enrolment in the Perceval Valve clinical study for Chinese Registration (“PERFECT”) TRIAL. This pre-market, prospective, single-arm trial study is being conducted to demonstrate the safety and effectiveness of Perceval Valve.

In December 2017, CryoLife Inc., announced the enrolment of patients for the company’s BioGlue clinical trial in China. The result from the trial will serve as the company’s regulatory submission to the Chinese Food and Drug Administration (CFDA) to gain approval to commercialize BioGlue in the country.

Globally, key players in the aortic valve industry are seeking for approvals to launch new products in the mar

FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.